Cargando…

Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study

Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B....

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Erin D., Antony, Joseph M., Crowley, David C., Piano, Amanda, Bhardwaj, Renu, Tompkins, Thomas A., Evans, Malkanthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230591/
https://www.ncbi.nlm.nih.gov/pubmed/32326347
http://dx.doi.org/10.3390/nu12041159
_version_ 1783534990259126272
author Lewis, Erin D.
Antony, Joseph M.
Crowley, David C.
Piano, Amanda
Bhardwaj, Renu
Tompkins, Thomas A.
Evans, Malkanthi
author_facet Lewis, Erin D.
Antony, Joseph M.
Crowley, David C.
Piano, Amanda
Bhardwaj, Renu
Tompkins, Thomas A.
Evans, Malkanthi
author_sort Lewis, Erin D.
collection PubMed
description Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes.
format Online
Article
Text
id pubmed-7230591
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72305912020-05-22 Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study Lewis, Erin D. Antony, Joseph M. Crowley, David C. Piano, Amanda Bhardwaj, Renu Tompkins, Thomas A. Evans, Malkanthi Nutrients Article Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes. MDPI 2020-04-21 /pmc/articles/PMC7230591/ /pubmed/32326347 http://dx.doi.org/10.3390/nu12041159 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lewis, Erin D.
Antony, Joseph M.
Crowley, David C.
Piano, Amanda
Bhardwaj, Renu
Tompkins, Thomas A.
Evans, Malkanthi
Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title_full Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title_fullStr Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title_full_unstemmed Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title_short Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study
title_sort efficacy of lactobacillus paracasei ha-196 and bifidobacterium longum r0175 in alleviating symptoms of irritable bowel syndrome (ibs): a randomized, placebo-controlled study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230591/
https://www.ncbi.nlm.nih.gov/pubmed/32326347
http://dx.doi.org/10.3390/nu12041159
work_keys_str_mv AT lewiserind efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT antonyjosephm efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT crowleydavidc efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT pianoamanda efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT bhardwajrenu efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT tompkinsthomasa efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy
AT evansmalkanthi efficacyoflactobacillusparacaseiha196andbifidobacteriumlongumr0175inalleviatingsymptomsofirritablebowelsyndromeibsarandomizedplacebocontrolledstudy